1. Veracyte, Inc. will present at Morgan Stanley's healthcare conference on September 9, 2025. 2. The conference may highlight Veracyte's diagnostic innovations and pipeline development. 3. Webcast available live and for 90 days post-event on Veracyte's website. 4. Veracyte aims to transform cancer care through advanced diagnostic technologies.
Participation in key healthcare events often boosts investor confidence. Historical evidence shows companies often experience positive price movements when showcasing innovations.
Engagement in significant healthcare conferences suggests potential growth and increased visibility within the sector.
Immediate investor interest may arise from the conference while future pipeline insights sustain longer-term effects.
Veracyte, Inc. (NASDAQ:VCYT) announced today that management will participate in a fireside chat at the Morgan Stanley 23rd Annual Global Healthcare Conference on Tuesday, September 9, 2025, at 4:50 p.m. Eastern Time.
A live audio webcast of the company's presentation will be available by visiting Veracyte's website at http://investor.veracyte.com/events-presentations. A replay of the webcast will be available for 90 days after the live presentation broadcast.
About Veracyte
Veracyte (NASDAQ:VCYT) is a global diagnostics company whose vision is to transform cancer care for patients all over the world. We empower clinicians with the high-value insights they need to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. Our Veracyte Diagnostics Platform delivers high-performing cancer tests that are fueled by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine, which ultimately drives durable reimbursement and guideline inclusion for our tests, along with new insights to support continued innovation and pipeline development. For more information, please visit www.veracyte.com or follow us on LinkedIn or X (Twitter).
View source version on businesswire.com: https://www.businesswire.com/news/home/20250829028322/en/
Investors:
Shayla Gorman
investors@veracyte.com
(619) 393-1545
Media:
Tracy Morris
media@veracyte.com
(650) 380-4413